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1. Introduction  
Depression is the most common form of affective disorders and may range from discrete to 
severe. Various studies have worked with the hypothesis that depression arises from the 
deficiency of monoamines (noradrenaline, serotonin and dopamine), the most adequate 
treatment being to raise the supply of these neurotransmitters in the central nervous system 
(CNS). Statistical data have shown that depression has increased as a result of the longer life 
expectancy and is common among the elderly population (Glassman et al., 1984). 
The treatment of psychiatric disorders and affective disturbances mainly involves 
antidepressant, antipsychotic and anxiolytic drugs. Studies relate that patients with 
psychiatric alterations that make use of these drugs complain of a dry mouth (Thomsom et 
al., 2000). Depressive alterations accompanied by the symptom of a dry mouth are 20% more 
frequent in women than in men (Bogetto et al., 1998) and the most affected age group ranges 
from 30 to 59 years (Scully, 2003). 
Antidepressants have an affinity for the adrenergic and cholinergic receptors present in the 
salivary glands and present an anticholinergic effect. The action of antidepressant drugs may 
be related to this affinity and the reduction of the cholinergic and sympathetic influx to the 
CNS.  The main side effect of these drugs is inhibition of the secretagogue effect caused by 
cholinergic stimulation, thus causing hyposalivation (Grégio et al., 2006). Other side effects 
include: nausea, dizziness, somnolence, sweating and tremors (Horst & Preskorn, 1998). 
Fluoxetine is a selective serotonin reuptake inhibitor (SRI) and, among others of the same 
class, is the result of research to find medications as effective as the tricyclic medications, but 
with fewer tolerability and safety problems. This drug does not inhibit the reuptake of other 
neurotransmitters, having no affinity for the adrenergic, muscarinic, cholinergic, H1-
histaminic or dopaminic receptors (Goldstein & Goodnick, 1998). Although they are 
considered safe drugs and present easily attainable therapeutic doses, the SRIs present 
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Venlafaxine is an antidepressant drug with a completely different chemical structure from that 
of other antidepressant agents. Its action mechanism resembles that of other known 
antidepressant, such as: fluoxetine, sertraline and paroxetine, since it is directly associated with 
potentiating neurotransmitter activity in the CNS (Makhija & Vavia, 2002; Owens et al., 2008). 
This drug is presented as a selective serotonin and noradrenalin reuptake inhibitor, and 
presents weak activity as a dopamine reuptake inhibitor, being clinically significant only at 
high doses (Goldstein & Goodnick, 1998). It does not present affinity for adrenergic 
receptors 1 and muscarinic or histaminic receptors (Diaz-Martinez et al., 1998; Goldstein & 
Goodnick, 1998). Consequently, it is less likely to produce side effects related to these 
pharmacologic properties (Denys et al., 2003). 
In a Cochrane systematic review (1966-2004), the adverse effects of fluoxetine (dry mouth 
sensation, dizziness and sudoresis) were compared with the adverse effects of the most 
recent antidepressants (venlafaxine, reboxetine, phenelzine, nefazodone) and they have 
shown to be less pronounced than in the latter (Cipriani et al., 2005).  
Normal salivation is essential for oral health due to its important contributions to the oral 
defence mechanisms. Diminished salivary secretion could lead to caries disease and 
deterioration of the mucosa (Mandel & Wotman, 1976; Mandel, 1980; Narhi, 1994). 
 
Fig. 1. Depression = affective disorders = depressive patient takes antidepressants drugs that 
cause dry mouth: alteration on salivary glands (parotid, sublingual and submandibul). 
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Salivary secretion is neurologically controlled by stimulation of reflex action. The salivary 
glands are enervated by the sympathetic and parasympathetic autonomic nervous system 
(ANS). Sympathetic enervation is linked by means of the type 2 and 2 adrenergic 
receptors (Baum, 1987), while parasympathetic enervation is linked to the muscarinic 
receptor M3. The primary acinar content is modified as it passes through the system of 
salivary gland ducts.  This process occurs because the cells of the duct receive stimuli from 
the sympathetic and parasympathetic pathways (Scully, 2003). 
Grégio et al. (2006), when studying the effects of the chronic use of the association of a 
benzodiazepine (Diazepam®) and an antidepressant (Tryptanol®) on the parotid glands of 
rats, observed hyposalivation and hypertrophy of serous cells. These findings suggested a 
possible inhibition of the activity of the myoepithelial cells, originating from nervous 
stimulation, a decrease in the number of such cells with the chronic use of psychotropic 
drugs or an alteration in the number of acinar and ductal cells. 
The aim of the present study was to verify the action of two drugs in the antidepressant class, 
fluoxetine and venlafaxine, on the salivary flow rate, as well as to make a histomorphometric 
analysis of the rat parotid glands submitted to chronic treatment with such drugs. 
2. Material and methods 
This study was approved by the Research Ethics Committee of Tuiuti University of Paraná, 
under the registration number CEP-UTP 55/2003.  
The animal model enrolled in this investigation consisted of male rats (Rattus norvegicus 
albinus, Wistar strain) obtained from the Central Animal Facility of the Pontifical Catholic 
University of Paraná. The animals weighed approximately 250g and were maintained in 
cages with water and food ad libidum on a light/dark cycle of 12 hours. 
Sixty animals, divided into six groups were used, each group consisting of 10 animals (Table 
1). The experimental groups received two antidepressants drugs, injectable solution of 
fluoxetine (lot 20040625,  Galena Química e Farmacêutica Ltda., Campinas, Brazil) and 
venlafaxine (lot D/VN/002/02, Galena Química e Farmacêutica Ltda., Campinas, Brazil). 
Controlled groups S30 and S60 received solution injectable from physiological serum and 
the P60 group received a gel base prepared with 1% from pilocarpine hydrochloride 








1. Experimental (FS) Fluoxetine 1-30 days 20mg/kg Intraperitoneal 
 Physiological Serum 31-60 days 0.1 mL Intraperitoneal 
2. Experimental (VS) Venlafaxine 1-30 days 40mg/kg Intraperitoneal 
 Physiological Serum 31-60 days 0.1 mL Intraperitoneal 
3. Experimental (F30) Fluoxetine 1-30 days 20mg/kg Intraperitoneal 
4. Experimental (V30) Venlafaxine 1-30 days 40mg/kg Intraperitoneal 
5. Control (S30) Physiological Serum 1-30 days 0.1 mL Intraperitoneal 
6. Control (S60) Physiological Serum 1-60 days 0.1 mL Intraperitoneal 
Table 1. Controls and experimental groups in accordance with the drug, treatment, time, 
dose and administration. 
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According to described methodology of Onofre et al. (1997), saliva samples were collected 
30 hours after the end of treatment. The animals had received two drops of 4% pilocarpine 
hydrochloride eye drops (Allergan pilocarpina® 4%, Allergan Produtos Farmacêuticos 
Ltda., Guarulhos, Brazil), to stimulate salivation. After one minute, saliva was collected in a 
collecting pot that was weighed on a high precision scale - Belmark® U210A (Bel 
Engenharia, Piracicaba, Brazil), obtaining thus a salivary flow rate (SFR).  
The values of amount of saliva were obtained in accordance with the described formula 
below (Banderas-Tarabay et al., 1997; Olsson et al., 1991). 
 
weight of pot after collection (g) - weight of pot before collection (g) =
weight saliva
= salivary flow rate (ml/min)
time (1 min)
  (1) 
2.2 Parotidean gland exsiccation and size measurement 
Glands were obtained from each group right after the saliva collection.  Rats were weighted 
and anaesthetised by intraperitoneal administration of 100 mg/kg sodium thiopental 
(Thionembutal®, Abbott Laboratórios do Brazil Ltda.) and killed. 
The right and left parotid glands were dissected and carefully removed. Fresh gland masses 
were determined with a BelMark® U210A precision scale. After this, the millimetric 
longitudinal dimensions were achieved using a high precision digital calliper - Mitutoyo 500 
Mical® (Mitutoyo Co., Tokyo, Japan). The average of the glands size and the glands mass 
was carried through, for attainment of variable so size (GS) and mass (M) for each rat. After 
the measurement of the part, gland tissue was fixed in 10% neutral formalin solution and 
embedded in paraffin. Four µm sections were obtained and submitted for routine 
haematoxylin-eosin (in accordance with the routine of the Laboratory of Experimental 
Pathology of the PUCPR). 
The microscopy Olympus® BX50 (Olympus Corporation, Ishikawa, Japan) was used with 
the objective of 40X and 100X (oil immersion). The images were captured with a digital 
camera - Sony® CCD-IRIS DXC-107A (Sony Eletronics Incorporation, Tokyo, Japan) 
connected to the microscope and a microcomputer. With a programme for analysis of 
images (Image-Pro® Plus, Cybernetics, Silverspring, U.S.A.), the histological analysis front 
to the use of antidepressants was evaluated. 
2.3 Histomorphometry of parotid glands 
To establish the comparisons among the groups with regard to the cellular volume (CV), the 
variable presented had been used in the study of Onofre et al. (1997).  
Processed gland volume (vp) was calculated for each animal using the following equation: 
 Vp=m/ d×rf  (2) 
M is fresh mass, d is density and rf is the shrinkage caused by histological processing. For 
these calculations we used d=1.089 g/cm3 and rf=0.7 using the method of Onofre et al. (1997). 
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For the stereological evaluation of acinar volume density (Vvi) and total volume (Vti) an 
objective of 40X it was used connected to the programme Image-Pro® Plus, where if it 
obtained a vertical grating with ten horizontal lines and ten vertical  lines, determining one 
hundred points of which forty had been chosen  randomly. In these, 40 chosen points had 
counted how many points coincided with acini (Pi). The Vvi by means of the formula was 
calculated then: 
 Vvi=Pi/Pt (3) 
Pt mentions the number to it of selected points 40.  
Having obtained the Vvi and processed gland volume (Vp) values, we calculated the total 
acinar volume (Vti) by the formula: 
 Vti = Vvi×Vp (4) 
Nuclear volume was determined from the measurement of the orthogonal diameters of 50 
nuclei per gland using a microscopy technique as stated before. We calculated the mean 
radius of the geometric mean diameter by: 
 r2 = d1×d2  (5) 
The nuclear volume was calculated by the formula for the volume of a sphere:  
 V=4/3×π×r3   (6) 
The cytoplasmic volume was calculated as of the nucleus densities and the cytoplasm of 
acinar cells (Weibel, 1969). In this respect, the points over nuclei (Pn) were counted and over 
the cytoplasm (Pcyti) in 40 histological fields of the cells under study. The corrected nuclear 
volume density (pncorr) was calculated by the equation: 
 pncorr = (Pn/Pn+Pcyti)/Ko  (7) 
Ko is the correction factor and is calculated by the formula: 
 Ko = 1+3t/2d (8) 
d is the mean nuclear diameter and t is section thickness. 
The corrected cytoplasm volume density is: 
 pcyticorr = 1- pncorr  (9) 
By dividing pcyticorr by pncorr the cytoplasm/nucleus ratio (RC/N) of the acinar cells was 
obtained. On the basis of nuclear volume (Vni) and the C/N ratio, the cytoplasmic volume 
(Vcyti) was calculated by the equation: 
 Vcyti = Vni×RC/N  (10) 
This then permitted calculating the cell volume by: 
 Vc= Vni + Vcyti   (11) 
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2.4 Statistical analysis 
To rest the presupposition of normality of the variables for each group, the Komolgorov-
Smirnov test was used. The Levene test verified the homogeneity of the variances among the 
groups. When the analysis of variance Anova found differences among the means of the 
groups and treatments, the Tukey HSD multiple comparisons test was used for the variables 
that presented homogeneity of variances among the groups. For the variables that did not 
present homogeneity of variances among the groups, the Games-Howell test was used. 
For all the tests the level of significance of 5% (p<0.05) was applied. 
3. Results 
All the groups presented normality of distribution of the data for the variables GS, M, SFR 
and CV of the studied glands (p>0.05), with the exception of the variable SFR in the group 
S60, the variable GS in groups FS and S30 and the variable M in the group F30. 
The variables GS and M showed homogeneity of variance (p>0.05) and the variables SFR 
and CV did not present homogeneity of variance (p<0.05). 
3.1 Groups treated for 30 days 
There was a statistically significant difference between the means of the variable GS among the 
following groups: F30 (p=0.0002), V30 (p=0.0112), when compared with group S30 (control).  
For the variable M, there was a statistically significant difference for the following groups: 
F30 and V30 (p=0.0011), F30 and S30 (p=0.0190), the highest mean being found for the group 
F30 and the lowest mean for the group V30. 
There was a statistically significant difference for the variable CV between the following 
groups: F30 (Figure 3) and S30 (p=0.0005), V30 and S30(p=0.0004). 
The variable SFR presented a statistically significant difference between groups: F30 and S30 
(p=0.0031). 
Table 2 shows the means and standard deviations of the studied variables in accordance 
with the groups treated for 30 days. 
 
Groups C30 F30 V30 
Variables Mean SD Mean SD Mean SD 
SFR (mL/min)δ 0.051  0.026  0.014   0.006  0.026  0.022  
CV (mm3)δ 6965.683   3792.951 10384.311  4869.539 11945.927  7891.179 
Gland size (mm) 7.036 0.506 9.501 1.404 8.696 1.409 
Mass (mg) 0.075 0.010 0.103 0.032 0.064 0.018 
serum - 30 days), F (fluoxetine - 30 days) and V (venlafaxine -30 days).  SD = standard deviations. 
δ: Values obtained from the study by Da Silva et al. (2009). 
SFR - Stimulated salivary flow rate. 
CV – Cellular volume. 
* Statistically significant difference among groups (p<0.05). 
Table 2.Values of studied variables in accordance with groups treated with C (physiological  
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Fig. 2. Histological aspect of the salivary gland of the fluoxetine 30 group showing 
disorganised glandular parenchyma. There was a loss of borders to the serous cells, which 
were also increased in size, with a consequent reduction or disappearance of the central 
lumen (H.E.; original magnification: 400X). 
Figures 3 and 4 show rat parotid glands from groups venlafaxine 30 and saline 30, respectively. 
 
Fig. 3. Histological aspect of the salivary gland of the venlafaxine 30 group. There was a loss 
of borders to the serous cells, which were also increased in size, with a consequent reduction 
or disappearance of the central lumen (H.E.; original magnification: 400X). 
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Fig. 4. Group saline 30. Well-structured glandular parenchyma divided into lobules. Inside 
the lobules, intercalary ducts were covered by cuboidal cells while striated ducts were found 
covered by columnar cells.  (H.E.; original magnification: 400X). 
3.2 Groups treated for 60 days 
Table 3 shows the means and standard deviations of the studied variables in accordance 
with the groups treated for 60 days. 
For SFR, there were statistically significant differences between the following groups: V60 
and C 60 (p=0.000).  
The variable GS did not show statistically significant differences among the groups. There 
were statistically significant differences for the variable M between groups VS and S60 
(p=0.0132). 
The variable CV did not showed statistically significant differences between groups C60, 
F60 and V60. 
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C60 F60 V60 
 Mean SD Mean SD Mean SD 
SFR (mL/min) δ 0.052 0.029 a 0.036 0.017 0.020 0.004 a 
CV (mm3) δ 6505.564 3343.475b 6809.347 3189.246c 7525.112 3196.085 
Gland size (mm) 7.885 0.628 8.350 0.077 8.040 0.949 
Mass (mg) 0.074 0.021 0.095 0.014 0.101 0.016 
δ: Values obtained from the study by Da Silva et al (2009). 
SFR - Stimulated salivary flow rate. 
CV – Cellular volume.  
a,b,c, groups followed by the same letter differed statistically from each other. 
* Statistically significant difference among groups (p<0.05). 
Table 3.Values of studied variables in accordance with groups treated with C (physiological 
serum -60 days), F (fluoxetine - 60 days) and V (venlafaxine -60 days).  SD = standard 
deviations. 
4. Discussion 
The anticholinergic effects of drugs that act on the CNS have not yet been completely 
explained. The majority of authors opt for defining the autonomic capacity of these drugs in 
linking to the adrenergic and cholinergic receptors, altering the quality and quantity of 
salivary flow. But several other factors must be considered, because in addition to 
interaction with and affinity to the sympathetic and parasympathetic CNS and ANS, other 
neurotransmitters, proteins and amino acids are capable of resulting in alteration of activity 
in the salivary glands (Scully, 2003). 
This study observed that fluoxetine (F30) produced an increase in GS and M of the rat 
parotid salivary glands, in addition to increasing CV in comparison with the control group 
S30. This effect probably occurred because the drugs with central action promote an action 
of salivary gland hypertrophy (Grégio et al., 2006). This result corroborates those of 
Martinez-Madrigal & Micheau (1989), who characterised hypertrophy of the glands by 
widening of the acini and accumulation of secretion granules, caused by drugs with central 
action. 
The anticholinergic action of psychotropic drugs (Martinez-Madrigal & Micheau, 1989; 
Scully, 2003) was proved once again, because in the group treated with fluoxetine for 30 
days (F30), the animals’ SFR was lower in comparison with the control group (S30), thus 
justifying the increase in GS and M, as there was retention of saliva in the acini lume and 
little of it being released. 
The antidepressants SRIs when compared to the tricyclic drugs have not presented 
significant effect on the flow rate, probably due to lack of anticholinergic activity. The flow 
reduction could occur through the serotonin receptor action presented at the peripheric 
microcirculation (Hunter & Wilson, 1995; Siepmann et al., 2003). According to Schubert & 
Izutsu (1987), the salivary flow can be affected by drugs through alteration of the blood flow 
to the salivary glands. For Grubb & Karas (1998) the seratonin has important physiology 
participation in the autonomic regulation since the CNS controls the sympathetic, the 
parasympathetic and the serotonin mechanisms, and therefore probably a decrease or 
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activation of the release of serotonin at the CNS would result in the alteration of both 
sympathetic and parasympathetic systems. This hypothesis contributes to our finding 
regarding the reduction of the SFR caused by fluoxetine. 
The uncertainty with regard to the exact biochemical mode of action of antidepressants 
frequently causes the development of new drugs to be empirical. This leads to the 
introduction of a heterogeneous group of compounds (to which venlafaxine belongs), the 
atypical antidepressants. In practice, the most recent drugs may definitively be superior to 
the tricyclic drugs in terms of side effects and acute toxicity, but they have not been shown 
to have a faster action or be more effective (Goldstein & Goodnick, 1998; Siepmann et al., 
2003). 
With regard to the results obtained for venlafaxine (V30), both GS and CV had higher values 
in comparison with the control group, and in addition there was diminished SFR when 
compared with the control (S30), once again demonstrating the anticholinergic action of 
psychotropic drugs and the effect of acinar cell hypertrophy (Grégio et al., 2006; Martinez-
Madrigal & Micheau 1989). 
Venlafaxine has fewer anticholinergic and adrenergic ǂ-blocker effects than the other 
antidepressive (Denys et al., 2003). This would cause a reduction in the adverse effects, 
because at low doses this drug predominantly blocks serotonin and noradrenalin reuptake, 
and at high doses it also inhibits dopamine reuptake. This hypothesis reinforces the great 
expectation in the use of venlafaxine in comparison with fluoxetine, and is in agreement 
with the present study findings, since the value of SFR for venlafaxine (V30) was higher 
when compared with the SFR value for fluoxetine (F30). Furthermore, fluoxetine has 
metabolite of prolonged action and is pharmacologically active (Goldstein & Goodnick, 
1998). 
The acinar cells present adrenergic  and ǃ receptors, vasoactive intestinal peptide receptors 
(VIP), acetylcholine and P substance. The receptors for ǃ adrenergic and for VIP, activate the 
cyclic AMP cascade, activating the G protein, which activates the adenylate cyclase enzyme. 
Whereas the  adrenergic receptors and the receptors for acetylcholine and P substance 
activate the inositol 1, 4, 5 triphosphate cascade (IP3) and of diacylglycerol. These 
biochemical reactions and interaction sequences influence both salivary secretion and 
composition (Berne et al., 2000).   
Because venlafaxine is a weak serotonin and noradrenalin reuptake inhibitor, it has fewer 
side effects than fluoxetine (De Nayer et al., 2002). Another hypothesis which could 
contribute to explaning the  result,besides the others mentioned before, is that the majority 
of types of serotoninergic receptors are coupled to the G proteins, affecting adenylate 
cyclase activity. This enzyme, in turn, converts ATP into the second messenger, cyclic AMP 
(Gould & Manji, 2002) which, as a central effect, presents activation of the protein kinase A 
(PKA), an enzyme that regulates ionic channels, which are responsible for the entry and exit 
of water and electrolytes from cells (Walton & Dragunow, 2000).  
On the other hand, the CV of rat parotid glands in the group treated with venlafaxine (V30) 
was greater than in the group treated with fluoxetine (F30). This is probably owing to the 
fact that venlafaxine (because it also inhibits noradrenalin reuptake and this being the 
mediator of the sympathetic ANS, which in turn tends to modulate the composition of 
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saliva) induces the protein secretion mechanism (Berne et al., 2000) which may be 
accumulating inside the salivary gland, resulting in cellular hypertrophy. 
The groups FS and VS presented lower SFR values than the group S60, proving that after 
suspension of the drug, withdrawal symptoms may occur, which appear within one to 10 
days and persists for up to three or four weeks. The most frequent symptoms are dizziness, 
vertigo, ataxia, gastrointestinal disorders, flu symptoms, sensorial disturbances, sleep 
alterations, psychic alterations and anticholinergic effects. As happens with other 
psychoactive substances, these symptoms may be the result of adaptive alterations, which 
most frequently involve the adjustment of the receptors to compensate for the 
pharmacological activity of the drug, described as a rebound effect (Goldstein & Goodnick, 
1998). 
The advances in research on the psychopharmacology of antidepressants have offered 
patients with very different pharmacokinetic profiles. In spite of this, the action mechanisms 
proposed for each of them remain linked to monoaminergic theories of increased amounts 
of neurotransmitters in the synaptic gap and the subsensitisation of presynaptic receptors 
(Paykel, 1992). 
In terms of the number of drugs available, there has been a considerable enlargement of the 
therapeutic arsenal, both with expansion in the number of compounds of the same 
pharmacological group, and in the appearance of drugs with different action profiles from 
those of the original ones. The more recent compounds are more selective, leading to greater 
tolerability and adherence to treatment (Goldstein & Goodnick, 1998). 
It is verified an effort in the sense of increasingly improving the action in receptor sites 
determinant of clinical efficacy, avoiding those responsible for side effects (Hunter & 
Wilson, 1995). However, new inquiries have become necessary due the complexity of the 
involved events in the saliva secretion mechanism. 
5. Conclusion 
It could be concluded that both fluoxetine and venlafaxine reduced the SFR and caused 
hypertrophy of the rat parotid gland, with fluoxetine having a more pronounced 
anticholinergic action.  
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